BrianBahmanBorgMD

Gastroenterology • Jackson, MS

Hepatology & Liver Transplantation

Physician

Join to view full profile

Dr. Borg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Borg's full profile

Already have an account?

Office
971 Lakeland Dr
Ste 1159
Jackson, MS 39216
Phone+1 769-251-5674

Fax+1 769-243-8130

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Gastroenterology, 2006 - 2009
Clinical Center at the National Institutes of HealthFellowship, Transplant Hepatology, 2003 - 2006
University of Maryland Capital Region HealthResidency, Internal Medicine, 2000 - 2003
Tehran University of Medical Sciences School of MedicineClass of 1992

Certifications & Licensure

LA State Medical License 2009 - 2026
MO State Medical License 2023 - 2026
CO State Medical License 2024 - 2025
MS State Medical License 2012 - 2025
KS State Medical License 2023 - 2024
MD State Medical License 2003 - 2018
American Board of Internal Medicine Gastroenterology
American Board of Internal Medicine Transplant Hepatology

Clinical Trials

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure Start of enrollment: 2013 Feb 01
Completed
Phase 3
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Start of enrollment: 2014 Dec 26
Terminated
Phase 4
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01
Completed
Phase 2
Study of Oral Treatments for Hepatitis C Start of enrollment: 2016 Jun 01
Completed
Phase 4
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Oct 24
Terminated
Phase 2
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) Start of enrollment: 2016 Nov 28
Completed
Phase 2
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124 Start of enrollment: 2016 Jul 31
Withdrawn
Early Phase 1
Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects Start of enrollment: 2017 Apr 20
Completed
Phase 3
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology Start of enrollment: 2017 Dec 08
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

17 citations
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Marlyn J Mayo, John M Vierling, Christopher L Bowlus, Cynthia Levy, Gideon M Hirschfield
Alimentary Pharmacology & Therapeutics. 2024-01-01
49 citations
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Stephen A Harrison, Manal F Abdelmalek, Guy Neff, Nadege Gunn, Cynthia D Guy
The Lancet. Gastroenterology & Hepatology. 2022-07-01
49 citations
A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis.
Mohammad S. Siddiqui, Michael O. Idowu, Deven Parmar, Brian B. Borg, Douglas Denham
Clinical Gastroenterology and Hepatology. 2021-12-01